Clinical Trials Directory

Trials / Completed

CompletedNCT02137031

Continuous Glucose Monitoring and Metabolic Control in Children With Type 1 Diabetes

Continuous Glucose Monitoring and HbA1c in Children for Longterm Diabetes Management

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
University of Toronto · Academic / Other
Sex
All
Age
6 Years – 18 Years
Healthy volunteers
Accepted

Summary

The primary purpose of this pilot randomized controlled trial is to provide preliminary indicators of the effects of continuous subcutaneous insulin infusion with continuous glucose monitoring compared to self-monitoring of blood glucose alone on: (1) metabolic control and (2) fear of hypoglycemia. Additional objectives will be: (1) to provide an estimate of recruitment rates, (2) to assess compliance with allocated treatment, and (3) to determine participants' satisfaction with allocated treatment. With increased and immediate information related to current and future (trend) glucose information provided by the continuous glucose monitor, children can then act upon this knowledge to prevent hypo- or hyperglycemia, thus, experiencing a reduction in glucose variability, leading to an improvement in metabolic control as shown by a reduction in HbA1c levels. Research on the effectiveness of continuous glucose monitoring on metabolic control in children with T1D using continuous subcutaneous insulin infusion has been limited. Therefore, a pilot clinical trial will be designed to provide preliminary indicators of the feasibility and acceptability of continuous glucose monitoring on metabolic control and address the following objectives.

Conditions

Interventions

TypeNameDescription
DEVICEMini Link REAL-Time TransmitterChildren used the Mini Link REAL-Time Transmitter to measure glucose continuously for a minimum of three days per week for three months.

Timeline

Start date
2012-09-01
Primary completion
2014-04-01
Completion
2014-04-01
First posted
2014-05-13
Last updated
2014-05-13

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT02137031. Inclusion in this directory is not an endorsement.